Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer

被引:15
|
作者
Minami, Seigo [1 ,2 ]
Ihara, Shouichi [1 ]
Komuta, Kiyoshi [2 ]
机构
[1] Osaka Police Hosp, Dept Resp Med, Tenn Ku, 10-31 Kitayama Cho, Osaka, Osaka 5430035, Japan
[2] Daini Osaka Police Hosp, Dept Resp Med, Tenn Ku, 2-6-40 Karasugatsuji, Osaka 5438922, Japan
关键词
Gustave Roussy immune score; Royal Marsden Hospital prognostic score; Extensive disease; Small cell lung cancer; Neutrophil-to-lymphocyte ratio; Number of metastatic sites; Lactate dehydrogenase; Serum albumin; TO-LYMPHOCYTE RATIO; PHASE-I; PROSPECTIVE VALIDATION; LACTATE-DEHYDROGENASE;
D O I
10.14740/wjon1275
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The Royal Marsden Hospital prognostic score (RMH score) and the Gustave Roussy inunune score (GRIm-score) were developed in order to select more suitable patient for phase I trials. Lactate dehydrogenase (LDH) and serum albumin concentration are common risk factors to these two systems. As the third risk factor, the RMII score and the GRIm-score adopt number of metastatic sites and neutrophil-to-lymphocyte ratio (NLR), respectively. We aimed to investigate whether these two systems are also useful for extensive disease of small cell lung cancer (ED-SCLC). Methods: We retrospectively collected 128 patients who had initiated platinum-based chemotherapy at our hospital between September 2007 and March 2018. We divided our patients into low (score 0 - 1) and high (2 - 3) score groups, and compared overall survival (OS) and progression-free survival (PFS) between them. Multivariate Cox proportional hazard analyses found prognostic factors of survival times. Results: Regarding GRIm-score, OS was significantly shorter in high score group than in low score group (median 6.1 vs. 11.4 months, P < 0.01), while no significant difference was observed in PFS (median 4.7 vs. 5.0 months, P = 0.12). Both OS (median 6.9 vs. 12.4 months, P < 0.01) and PFS (median 4.4 vs. 5.4 months, P = 0.01) were significantly shorter in high RMH score group than in low group. Multivariate analyses detected both high GRIm-score (hazard ratio (HR) 1.80, 95% confidence interval (CI) 1.20 - 2.72, P < 0.01) and high RMH score (HR 1.93, 95% CI 1.27 - 2.92, P < 0.01) as independent worse prognostic factors of OS, and then only high RMI1 score (FIR 1.53, 95% CI 1.04 - 2.25, P = 0.03) as independent worse prognostic factor of PFS. Conclusions: Both RMH score and GRIm-score are useful as inde- pendent prognostic factors of OS in ED-SCLC. However, only RMH score is an independent prognostic factor of PFS.
引用
收藏
页码:98 / 105
页数:8
相关论文
共 50 条
  • [1] Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer
    Minami, Seigo
    Ihara, Shouichi
    Ikuta, Shouko
    Komuta, Kiyoshi
    WORLD JOURNAL OF ONCOLOGY, 2019, 10 (02) : 90 - 100
  • [2] Prognostic Value of the Gustave Roussy Immune Score in Lung Cancer: A Meta-Analysis
    Ji, Yanli
    Wang, Wenping
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2024, 76 (08): : 707 - 716
  • [3] Gustave Roussy Immune Score (GRIm-Score) as a Prognostic and Predictive Score in Metastatic Colorectal Cancer
    Cotan, Horia
    Iaciu, Cristian
    Radu, Emilescu
    Niculae, Tudor
    Rosu, Oana A.
    Nitipir, Cornelia
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [4] Prognostic value of Gustave Roussy immune score in operable pancreatic adenocarcinoma
    Basoglu, Tugba
    Babacan, Nalan A.
    Ozturk, Fatih E.
    Arikan, Rukiye
    Demircan, Nazim C.
    Telli, Tugba Akin
    Ercelep, Ozlem
    Dane, Faysal
    Yumuk, Perran F.
    INDIAN JOURNAL OF CANCER, 2023, 60 (02) : 179 - 184
  • [5] Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study
    Jian, Shangguan
    Huang, Xinyi
    Liu, Xu
    Zhang, Zengfu
    Zhang, Xiaodong
    Yu, Jinming
    Chen, Dawei
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] The prognostic role of Gustave Roussy Immune Score (GRIm-Score) in metastatic lung adenocarcinoma patients treated with chemotherapy
    Soyler, Yasemin
    ozturk, Ayperi
    ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, 2023, 14 (07): : 640 - 645
  • [7] Prognostic ability of the Gustave Roussy Immune Score for patients with advanced pancreatic adenocarcinoma
    Ma, Lucy Xiaolu
    Holzapfel, Nicholas Timothy
    Wang, Yifan
    Ramotar, Stephanie
    Allen, Michael J.
    Jang, Gun Ho
    Zhang, Amy
    Dodd, Anna
    Hutchinson, Shawn
    Tehfe, Mustapha
    Ramjeesingh, Ravi
    Biagi, James Joseph
    Wilson, Julie
    Notta, Faiyaz
    Fischer, Sandra
    Zogopoulos, George
    Gallinger, Steven
    Grant, Robert C.
    Knox, Jennifer J.
    O'Kane, Grainne M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] Prognostic significance of the Gustave Roussy immune (GRIm) score in cancer patients: a meta-analysis
    Sun, Ke-Xin
    Xu, Ru-Qin
    Rong, Huan
    Pang, Hua-Yang
    Xiang, Ting-Xiu
    ANNALS OF MEDICINE, 2023, 55 (02)
  • [9] Evaluation of the prognostic importance of Gustave Roussy immune score in hepatocellular carcinoma patients
    Firat, Hatice Gulgun
    Onur, Ilknur Deliktas
    Camoz, Elif Sertesen
    Yildiz, Fatih
    JOURNAL OF HEPATOLOGY, 2024, 80 : S407 - S407
  • [10] Gustave Roussy Immune Score as a Novel Prognostic Scoring System for Colorectal Cancer Patients: A Propensity Score Matching Analysis
    Tian, Shan
    Cao, Yinghao
    Duan, Yanran
    Liu, Qi
    Peng, Pailan
    FRONTIERS IN ONCOLOGY, 2021, 11